Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832120 | 0.79 | KDM4E (0.35) | S1PR4KDM4EALDH1A1KDM5BTSHR | |
| SCHEMBL756047 | 0.79 | KDM4E (0.35) | S1PR4KDM4EALDH1A1KDM5BTSHR | |
| SCHEMBL29364954 | 0.77 | KDM4E (0.34) | S1PR4KDM4EALDH1A1KDM5BTSHR | |
| SCHEMBL160005 | 0.77 | KDM4E (0.34) | S1PR4KDM4EALDH1A1KDM5BTSHR | |
| SCHEMBL10924648 | 0.74 | S1PR4 (0.39) | S1PR4KDM4EALDH1A1KDM5BTSHR | |
| SCHEMBL10394906 | 0.74 | MAPKAPK2 (0.44) | TSHR | |
| SCHEMBL108874 | 0.73 | JAK3 (0.35) | S1PR4KDM4EALDH1A1KDM5B | |
| SCHEMBL29666109 | 0.73 | JAK3 (0.35) | S1PR4KDM4EALDH1A1KDM5B | |
| SCHEMBL9458929 | 0.72 | — | — | |
| SCHEMBL29350484 | 0.71 | JAK3 (0.32) | S1PR4KDM4EALDH1A1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| EP-3194403-B1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2019-02-06 | — | — | EP | disclosed |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-10-25 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR4 1141/4885KDM4E 1986/4885ALDH1A1 1595/4885 |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | S1PR4 1141/4885KDM4E 1986/4885ALDH1A1 1595/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR4 1141/4885KDM4E 1986/4885ALDH1A1 1595/4885 |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR4 1141/4885KDM4E 1986/4885ALDH1A1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.